In recent years, several molecularly targeted therapies have been approved for clear cell renal cell carcinoma (ccRCC), a highly aggressive cancer. Although these therapies significantly extend overall survival, nearly all patients with advanced ccRCC eventually succumb to the disease. To identify other molecular targets, we profiled gene expression in 90 ccRCC patient specimens for which tumor grade information was available. Gene set enrichment analysis indicated that cell cycle-related genes, in particular Polo-like kinase 1 (PLK1), were associated with disease aggressiveness. We also performed RNAi screening to identify kinases and phosphatases that when inhibited could prevent cell proliferation. As expected, RNAi-mediated knockdown of PLK1 and other cell cycle kinases was sufficient to suppress ccRCC cell proliferation. The association of PLK1 in both disease aggression and in vitro growth prompted us to examine the effects of a small-molecule inhibitor of PLK1, BI 2536, in ccRCC cell lines.
Introduction
In 2010 in the United States, an estimated 58,000 people will be diagnosed with, and 35 ,000 deaths will be attributed to, cancers of the kidney and renal pelvis (1) . Kidney cancer can be divided into several histological subtypes, but the majority of the cases (about 75%) are of the clear cell renal cell carcinoma (ccRCC) subtype (2) . Surgery offers the best opportunity to cure localized ccRCC. However, most patients who experience recurrence after surgery or who have metastatic disease at the time of diagnosis will ultimately succumb to the disease.
Immunotherapy with agents such as IL-2 has been the only choice for metastatic RCC patients, with 7-8% of individuals showing complete remission following treatment (3, 4) , but IL-2 is beneficial to only a small number of patients. New agents such as sunitinib, sorafenib, and pazopanib, which target the receptor tyrosine kinases of vascular endothelial growth factor (VEGFR) and platelet-derived growth factor (PDGFR), have recently been approved by the FDA for ccRCC therapy, but the responses are usually partial and most patients eventually experience progression (5, 6) . Therapies directed against the mammalian target of rapamycin (mTOR) have also been used to treat advanced disease, but again most patients have disease progression (7) .
Thus, there remains a critical need for effective and specifically targeted therapies for ccRCC.
Gene expression profiling has been successfully used to find genes that are differentially expressed among RCC subtypes, correlated with chromosomal abnormalities, or correlated with deregulated oncogenic pathways (8) (9) (10) . However, finding therapeutic targets from those lists of genes is still challenging. Genes whose expression varies with clinical parameters such as tumor grade, stage, or survival duration may be more helpful in identifying molecular targets, but they require additional validation (11, 12) .
The discovery of RNA interference (RNAi) and the advance of technologies for using RNAi on large sets of genes in mammalian cells-either small interfering RNA (siRNA) or short hairpin RNA (shRNA)-allow us to systematically interrogate gene functions at high throughput (13) (14) (15) (16) . Such an approach has proven successful in the discovery of genes that were components of the p53 tumor-suppressor pathway (13) , of genes that when knocked down sensitize resistant cells to chemotherapeutic agents (15, 16) , and of genes essential to the proliferation of human mammary and colon cancer cells (17, 18 ).
Here we expand upon previous partial kinase library screening of ccRCC (19) by examining the effects on cell proliferation within the whole library of kinases and phosphatases.
In addition, we used expression profiling data performed on 90 ccRCC samples for which we had tumor grade information. Combining these results identified a class of cell-cycle kinases, such as Polo-like kinase 1 (PLK1), as potential therapeutic targets for ccRCC.
Materials and Methods
Tissue collection and gene expression profiling. Gene expression profiles from 90 ccRCC tumors and 13 normal kidney samples were produced as previously described (10, 20) .
This data has been deposited at the Gene Expression Omnibus (GSE 17895). The kidney samples were obtained from the Cooperative Human Tissue Network, and approval was obtained from the Van Andel Research Institute Institutional Review Board to study the samples. Gene expression analysis was performed as previously described (21, 22) .
The genes differentially expressed between the weakly aggressive group of tumors (Grade I and II) and the highly aggressive tumors (Grade IV) were identified using the function of the linear model for a series of arrays (lmFit) as stated in the limma package (23).
For Gene Ontology gene enrichment analysis, significant GO terms were calculated using the Fisher test (raw P value) or elim Fisher test (adjusted P value) as stated in the topGO package (24) . Survival analysis. Gene expression profiles from 179 ccRCC tumors with following survival duration after surgery were used to perform survival analysis as previously described (25) .
Statistical analysis. For all statistical analyses, values were expressed as mean ± standard deviation (s.d), except that the relative gene expression values from microarrays were expressed as median ± median absolute deviation (MAD) (26) . Values were compared using Student's t test; P < 0.05 was considered significant. siRNA library screening and target identification. Custom siRNA human kinase and phosphatase library sets were designed and synthesized as previously described (15) . Our validation data showed greater than 93% transfection efficiency in ccRCC cell lines, and this library has been observed to induce, on average, greater than 80% knock-down for each mRNA target species in our previously published study (15) and this current study.
786-O cells (WT2 or RC3) were seeded onto 96-well plates at 1000 cells per well.
Twenty-four hours later, 10 µl of siRNA and lipid (Oligofectamine TM , Invitrogen, Carlsbad, CA) mix was added to each well. Cell viabilities were analyzed four days after transfection using the CellTiter 96® AQueous assay (MTS assay; Promega, Madison, WI).
For proliferation analyses, B-score normalization was applied to primary screening MTS OD values to eliminate plate-to-plate variability and well-position effects (26) . IHC staining for phosphorylated histone H3 (Ser10) was performed as described (20) .
Phosphorylated histone H3 (Ser10) antibody (Cell Signaling) was used at a dilution of 1:50. The quantification of proliferation index was also performed as previously described (20) .
Results
Genes associated with aggressive ccRCC. Gene expression profiling was performed on 90 ccRCC patient samples for which tumor grade information was available (Suppl. Tab. 1). To identify individual genes whose expression is associated with tumor aggressiveness, we first filtered out genes that did not show much difference among the patients, using 1.414 (log2 value < 0.5) as the cutoff for interquartile expression levels. This left about half the genes (9824/18,185)
as candidates for further analysis. Then we classified the patients into two groups, weakly aggressive (Grade I and II) and highly aggressive (Grade IV). A linear model was used to identify genes differentially expressed between these two groups. We identified 1159 genes as being significantly associated with aggressiveness when highly expressed (FDR < 0.2 and fold change > 1, Fig. 1A and Suppl. Tab. 2).
High expression of cell cycle-related kinases is associated with tumor aggressiveness.
To place the individual genes into biological context, a gene enrichment analysis approach based on Gene Ontology (GO) was used (29) . When the Biological Process GO categories were examined, six out of the top ten GO terms were associated with the cell cycle, for example, the GO terms "mitosis" (GO:0007067, raw P = 4.30 × 10 -13 , adjusted P = 4.30 × 10 -13 ) and "cellcycle phase" (GO:0022403, raw P = 1.60 × 10 -13 , adjusted P = 0.024, Suppl. Tab. 3 and Suppl. Fig. 1 ). The GO term "cell cycle" (GO:0007049) was the highest level of parent node for these six related significant nodes, and it was itself also significantly related to aggressiveness (raw P = 2.3 × 10 -12 , adjusted P = 0.11, Suppl. Fig. 1 and Suppl. Tab. 3). Within the GO term "cell cycle", 117 genes were identified as being associated with aggressiveness, representing 10.1%
(117/1159) of the aggressiveness-related genes (Fig. 1A) . Thus, genes associated with the cell cycle were strongly associated with ccRCC aggressiveness.
When the analysis was performed using the Molecular Function GO categories, one of the significant related nodes was the GO term "kinase activity" (GO:0016301, raw P = 4.14 × 10 -3 , adjusted P = 0.19), which is the parent node of GO terms of "protein kinase activity" (GO:0004672, P = 5.97 × 10 
Importance of cell cycle kinases for ccRCC cell line proliferation in vitro.
We used a cell-based assay to identify genes that were essential to ccRCC cell proliferation, and we performed a high-throughput siRNA screen targeting the whole kinome and phosphatome using an isogenic pair of ccRCC cell lines, 786-O (RC3, VHL-) and 786-O (WT2, VHL+) (30), trying to find targets specific required for VHL-mutated cell proliferation. Each cell line was transfected with four unique siRNA duplexes targeting each of 678 known and putative kinases and 198 known and putative phosphatases in a one-gene/one-well format on 96-well microtitre plates. The transfection efficiency was greater than 93% (Suppl. Fig. 5 ). At 96 h after transfection, cell proliferation was measured using an MTS assay, which measures the activity of reductase enzymes in living cells (31) . Raw absorbance values were normalized to internal reference control samples on each plate to permit plate-to-plate comparisons, and each well was assigned a B-score after normalization of the position effects (26) . Although we started with the idea of finding synthetic lethal genes, we did not find such targets except for the genes which have been reported before (19) . Next, we used the average B-score from these two cell lines to choose positive hits regardless of VHL status (Suppl. Tab. 5).
In this screen, siRNAs having an average B-score of less than -3 were defined as proliferation genes for ccRCC ( Fig. 2A) . Overall, we identified 35 kinases, including PLK1, nonmetastatic cells 3 (NME3), cell cycle-related kinase (CCRK), NAD kinase (NADK), and PCTAIRE protein kinase 3 (PCTK3), as well as two phosphatases, protein phosphatase 1 regulatory (inhibitor) subunit 3F (PPP1R3F) and 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 (PFKFB2). To get a functional overview of these data, the genes were classified according to function; the majority of hits were metabolic and cell cycle kinases and phosphatases (Fig. 2B) . A subset of these genes was selected for further study. To rule out potential off-target and cell line effects of the siRNA screen, each gene was targeted with four different siRNAs individually in the 786-O, A498, ACHN, Caki-1, and SN12C cell lines. To rule out potential assay effects, proliferation rates were measured by quantitation of ATP levels (CellTiter-Glo) rather than by reductase activity (32). All ccRCC cell lines showed a similar requirement, regardless of VHL status, for the NME3, PLK1, CCRK, NADK, PCTK3, deoxyguanosine kinase (DGUOK), and glucokinase (GCK) genes for cell survival in vitro (Fig. 2C and Suppl. Fig. 6A ).
To confirm these results, 786-O cells were transfected with four siRNAs individually targeting one of five different kinases. The cells were transferred to six-well plates and allowed to grow for 8-10 days, and then were stained with crystal violet to visualize the relative number of cell colonies (Fig. 2D and Suppl. Fig. 6B ). At the same time, the mRNA levels for the kinases were measured using quantitative PCR (Q-PCR) following knock-down by single siRNAs (Fig.   2E and Suppl. Fig. 6C ). The results were consistent, showing that the effective siRNAs were targeting their specific targets and that a decrease of candidate gene expression was associated with decreased cell proliferation. In summary, we identified 37 genes, including PLK1, that are important to ccRCC cell line proliferation in vitro ( Table 1) .
Inhibition of PLK1 function suppresses ccRCC cell proliferation in vitro.
The combined results of the aggressiveness analysis and the cell line proliferation screening indicated that cell cycle-related genes were important to both disease progression and cell proliferation.
Specifically, we found that three kinases (AURKB, PLK1, and JAK3) were identified in both data sets (Suppl. Fig. 7 ). We previously examined the role of the Aurora kinases in ccRCC, showing that inhibition of this class of kinases suppresses the growth of ccRCC (25 examine the effects of PLK1 inhibition on ccRCC. The cell lines 786-O, A498, ACHN, Caki-1, and SN12C were treated for 96 h with concentrations of BI 2536 from 5 nM to 80 nM (Fig. 3A) .
These concentrations were previously reported to inhibit PLK1 kinase activity in vitro (33, 34) . (Fig. 3B ). Cells treated with nocodazole were used as a control population blocked at G2/M phase.
As expected, the cells treated with BI 2536 accumulated at G2/M, which is consistent with the function of PLK1 in early mitotic entry. Sustained evidence indicates that the level of histone H3 phosphorylated on serine 10 (pH3) correlates with proliferation rate and that the intracellular pattern of pH3 staining differentiates between stages of mitosis (37), so next we examined both pH3 levels and the chromosome orientation. Compared with either non-treated or buffer controls, BI 2536-treated cells had increased levels of pH3, reaching the level found in cells treated with nocodazole (Fig. 3C ). Cells were also stained with α-tubulin, followed by CAN-11-0076 phenotype. The number of cells with the Polo phenotype was substantially increased in the BI 2536 treatment group relative to controls, indicating that the inhibition of PLK1 function results in an M-phase block that is associated with decreased cellular proliferation (Fig. 3D) . Then we used the same treatment schedule, but we applied BI 2536 to 786-O xenografts by intratumoral injection. Under this protocol, tumors were allowed to grow to 200 mm 3 , and then 50 mg/kg BI 2536 was injected intratumorally according to the dosing schedule. After two cycles of treatment, no effect on tumor growth was observed. We speculated that the tumor was not responsive due to the incomplete inhibition of PLK1 function. Thus, in subsequent treatments, 50 mg/kg of BI 2536 was injected twice a day (100 mg/kg total per day), once at 7:00 am and then at 5:00 pm, for two consecutive days in a week. Somewhat surprisingly, the tumors significantly regressed upon this BI 2536 treatment (Fig. 4A) , and we repeatedly observed similar effects on both 786-O (data not shown) and A498 ccRCC xenografts (Fig. 4B ).
To confirm that BI 2536 inhibited PLK1 function using the twice-a-day schedule in vivo, a target modulation study was performed. 786-O cells were subcutaneously implanted in nude mice, tumors were allowed to grow to 400-500 mm 3 , and then the mice were treated by intratumoral injection three times, twice in the first day and once in the following day, using 50 mg/kg BI 2536 per injection. The mice were sacrificed 6 hours after the final injection. The 
Discussion
This study integrated both gene expression profiling and RNAi screening data to identify genes involved in ccRCC development and progression. Consistent with cancer being a disease of uncontrolled proliferation, we found an enrichment of cell cycle-related processes when genes associated with tumor grade were examined for deregulated biological pathways. However, the appearance of kinase-related genes in the molecular function analysis was not initially expected, because ccRCC renal tumors have not been reported to contain specific kinase-associated pathway activation induced by either gene mutation or focal amplification (33, 38, 39) .
Based on the gene expression results and the generation of several potent small-molecule kinase inhibitors, we performed an RNAi screen to identify kinases and phosphatases that were required for the growth of ccRCC cell lines. Both our expression analysis and our siRNA proliferation screen highlighted the importance of cell cycle-related genes like PLK1 and AURKB in ccRCC. PLK1 is a serine-threonine kinase that plays a key role in mitotic entry, centrosome maturation, and cytokinesis (35) . Consistent with our finding that PLK1 is overexpressed in high-grade kidney cancers, PLK1 has been found overexpressed in many other solid tumor types (40) , including breast cancer (41) and colorectal cancer (42). As we report here Our data reported here and previously (25) clearly show that inhibition of PLK1 or AURKB function can suppress ccRCC tumor growth both in vitro and in vivo. However, one of the most notable results of this work was that a twice-a-day schedule is required for the in vivo effects of BI 2536. This result may indicate that for cell-cycle kinase inhibitors to cause ccRCC tumor regression, the function of the kinases needs to be inhibited for a longer duration than is needed by, for example, receptor tyrosine kinase inhibitors. We speculate that to induce cell death or apoptosis in ccRCC, the function of PLK1 needs to be suppressed for a certain period, highlighting the need for careful selection of delivery schedules for this class of drugs in clinical trials for ccRCC.
We also indentified a series of proliferation genes for ccRCC; in particular, NME3 (also known as DR-nm23) seemed to potently suppress the growth of these cells when knocked down.
NME3 belongs to the nm23 gene family having a common nucleoside diphosphate kinase (NDPK) activity (46) . NME3 has been shown to either inhibit or promote cell differentiation or apoptosis when highly expressed in different cell types (47) . Genes from the same family have been shown to be closely related to metastasis (48) . Whether the kinase activity of NME3 is required for ccRCC cell proliferation could be a fruitful area for further study. than-average expression (black) or lower-than-average expression (grey) and evaluated for differences in patient cancer-specific survival using the Kaplan-Meier method. 
